BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Hu J, Yu A, Othmane B, Guo T, Liu J, Cheng C, Chen J, Zu X. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Front Oncol 2021;11:642159. [PMID: 33816290 DOI: 10.3389/fonc.2021.642159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cai Z, He Y, Yu Z, Hu J, Xiao Z, Zu X, Li Z, Li H. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. Front Immunol 2022;13:933241. [DOI: 10.3389/fimmu.2022.933241] [Reference Citation Analysis]
2 Li H, Zu X, Hu J, Xiao Z, Cai Z, Gao N, Chen J. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma. Front Immunol 2022;13:964393. [DOI: 10.3389/fimmu.2022.964393] [Reference Citation Analysis]
3 Deng D, Liu F, Liu Z, Wu Z, He Y, Zhang C, Zu X, Ou Z, Wang Y. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma. Front Immunol 2022;13:965469. [DOI: 10.3389/fimmu.2022.965469] [Reference Citation Analysis]
4 Wen H, Tang J, Cui Y, Hou M, Zhou J. m6A modification-mediated BATF2 suppresses metastasis and angiogenesis of tongue squamous cell carcinoma through inhibiting VEGFA. Cell Cycle 2022;:1-17. [PMID: 35949109 DOI: 10.1080/15384101.2022.2109897] [Reference Citation Analysis]
5 Mao S, Chen Z, Wu Y, Xiong H, Yuan X, Han H. Crosstalk of Eight Types of RNA Modification Regulators Defines Tumor Microenvironments, Cancer Hallmarks, and Prognosis of Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/1285632] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li X, Wang S, Chen D, Liu H, You J, Su L, Yang X. Construction and Validation of a m7G-Related Gene-Based Prognostic Model for Gastric Cancer. Front Oncol 2022;12:861412. [DOI: 10.3389/fonc.2022.861412] [Reference Citation Analysis]
7 Yu M, Liu X, Xu H, Shen S, Wang F, Chen D, Li G, Wang Z, Zuo Z, Zhao A. Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Front Immunol 2022;13:818120. [DOI: 10.3389/fimmu.2022.818120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu S, Li Z, Li H, Wen X, Wang Y, Chen Q, Xu X. TGFβ-Associated Signature Predicts Prognosis and Tumor Microenvironment Infiltration Characterization in Gastric Carcinoma. Front Genet 2022;13:818378. [DOI: 10.3389/fgene.2022.818378] [Reference Citation Analysis]
9 Wang R, Guo Y, Ma P, Song Y, Min J, Zhao T, Hua L, Zhang C, Yang C, Shi J, Zhu L, Gan D, Li S, Li J, Su H. Comprehensive Analysis of 5-Methylcytosine (m5C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy. Front Oncol 2022;12:851766. [PMID: 35433474 DOI: 10.3389/fonc.2022.851766] [Reference Citation Analysis]
10 Zou C, He Q, Feng Y, Chen M, Zhang D. A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. NAR Cancer 2022;4:zcac010. [PMID: 35350771 DOI: 10.1093/narcan/zcac010] [Reference Citation Analysis]
11 Liu Z, Qi T, Li X, Yao Y, Othmane B, Chen J, Zu X, Ou Z, Hu J. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer. Front Immunol 2021;12:791924. [PMID: 34975891 DOI: 10.3389/fimmu.2021.791924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ning X, Li N, Qi Y, Li S, Jia Z, Yang J. Identification of a Hypoxia-Related Gene Model for Predicting the Prognosis and Formulating the Treatment Strategies in Kidney Renal Clear Cell Carcinoma. Front Oncol 2022;11:806264. [DOI: 10.3389/fonc.2021.806264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xie J, Cui L, Pan S, Liu D, Liu F, Liu Z, Zhang Y. Metabolic Understanding of the Genetic Dysregulation in the Tumor Microenvironment of Kidney Renal Clear Cell Carcinoma. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/6085072] [Reference Citation Analysis]
14 Tao N, Li H, Deng L, Zhao S, Ouyang J, Wen M, Chen W, Zeng K, Wei C, Liu YN. A Cascade Nanozyme with Amplified Sonodynamic Therapeutic Effects through Comodulation of Hypoxia and Immunosuppression against Cancer. ACS Nano 2021. [PMID: 34962762 DOI: 10.1021/acsnano.1c07504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang Y, Xu M, Yue P, Zhang D, Tong J, Li Y. Novel Insights Into the Potential Mechanisms of N6-Methyladenosine RNA Modification on Sepsis-Induced Cardiovascular Dysfunction: An Update Summary on Direct and Indirect Evidences. Front Cell Dev Biol 2021;9:772921. [PMID: 34869371 DOI: 10.3389/fcell.2021.772921] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
16 Hu J, Othmane B, Yu A, Li H, Cai Z, Chen X, Ren W, Chen J, Zu X. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Med 2021;19:289. [PMID: 34836536 DOI: 10.1186/s12916-021-02163-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chen Y, Liang Y, Chen Y, Ouyang S, Liu K, Yin W. Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma. J Oncol 2021;2021:2042114. [PMID: 34616452 DOI: 10.1155/2021/2042114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Zhan L, Zhang J, Zhu S, Liu X, Zhang J, Wang W, Fan Y, Sun S, Wei B, Cao Y. N6-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors. Front Cell Dev Biol 2021;9:736298. [PMID: 34616742 DOI: 10.3389/fcell.2021.736298] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Quan C, Belaydi O, Hu J, Li H, Yu A, Liu P, Yi Z, Qiu D, Ren W, Ma H, Gong G, Ou Z, Chen M, Sun Y, Chen J, Zu X. N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target. Front Immunol 2021;12:697026. [PMID: 34526985 DOI: 10.3389/fimmu.2021.697026] [Cited by in F6Publishing: 5] [Reference Citation Analysis]